mA-Methylated NUTM2B-AS1 Promotes Hepatocellular Carcinoma Stemness Feature via Epigenetically Activating Transcription.

Purpose: Hepatocellular carcinoma (HCC) is one of the most lethal malignancies in the world. Oncofetal proteins are the optimal diagnostic biomarkers and therapeutic targets for HCC. As the most abundant modification in RNA, N-methyladenosine (mA) has been reported to be involved in HCC initiation and progression.

METTL3 and METTL14-mediated N-methyladenosine modification of SREBF2-AS1 facilitates hepatocellular carcinoma progression and sorafenib resistance through DNA demethylation of SREBF2.

As the most prevalent epitranscriptomic modification, N-methyladenosine (mA) shows important roles in a variety of diseases through regulating the processing, stability and translation of target RNAs. However, the potential contributions of mA to RNA functions are unclear. Here, we identified a functional and prognosis-related mA-modified RNA SREBF2-AS1 in hepatocellular carcinoma (HCC).

mA modification of AC026356.1 facilitates hepatocellular carcinoma progression by regulating the IGF2BP1-IL11 axis.

N-methyladenosine (mA) is the most common RNA modification in eukaryotic RNAs. Although the important roles of mA in RNA fate have been revealed, the potential contribution of mA to RNA function in various diseases, including hepatocellular carcinoma (HCC), is still unclear. In this study, we identified a novel mA-modified RNA AC026356.